Zomedica Corp. announced the commercial launch of its newest assay - endogenous ACTH (eACTH) for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. PPID or Cushing's disease is one of the most common endocrine disorders in horses and ponies.

Left undiagnosed and untreated, quality of life for these animals will rapidly decline and their life expectancy will shorten. The measurement of baseline eACTH is widely accepted as the most effective way to help diagnose PPID and plays an essential role in disease management, but until now, to test eACTH levels, blood samples needed special handling and shipping to remote labs, risking sample degradation or even loss. The TRUFORMA eACTH assay for equine plasma will offer equine veterinarians the ability to diagnose and screen for PPID as well as monitor patients being treated for PPID in their own labs or even stall side in minutes.

The TRUFORMA device, being compact, easy to use, and durable, is a great fit for the unique challenges that face equine practitioners.